Physician profile
Alan M Kramer
NPI 1356357347
$12,088.14
in general payments reported to CMS, 2019-2025
46 companies · $3,712 in 2025
The $3,712 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $1,416 · 2021: $726 · 2022: $582 · 2023: $1,559 · 2024: $2,537 · 2025: $3,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,654 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,654.00 |
| Education | $153.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,606.44 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,480.57 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $850.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $818.10 | 2019-2025 | Kisqali |
| Merck Sharp & Dohme LLC | $782.22 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $561.72 | 2019-2025 | Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $435.25 | 2020-2025 | Enhertu, Datroway |
| Array Biopharma INC | $394.43 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $380.03 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $360.48 | 2022-2025 | Libtayo |
| Seagen INC. | $327.73 | 2019-2023 | Tukysa |
| Coherus Oncology, INC. | $301.50 | 2023-2025 | Loqtorzi |
| Eisai INC. | $298.06 | 2019-2025 | |
| Stemline Therapeutics INC. | $291.48 | 2024-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $278.28 | 2019-2025 | Fruzaqla, Alunbrig |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $267.51 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $248.89 | 2019-2025 | Venclexta, Tecentriq, Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $236.53 | 2019-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $219.55 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Celgene Corporation | $216.56 | 2019-2025 | Opdivo, Reblozyl |
| Intuitive Surgical, INC. | $196.18 | 2021 | |
| Exelixis INC. | $182.08 | 2019-2020 | |
| Amgen INC. | $129.25 | 2020-2023 | Kyprolis, Xgeva, Vectibix |
| Genzyme Corporation | $118.38 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $113.73 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $105.75 | 2019-2025 | |
| Puma Biotechnology, INC. | $81.61 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $76.88 | 2021-2024 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $68.39 | 2023-2025 | Qinlock, Romvimza |
| Immunocore Limited | $67.70 | 2024-2025 | Kimmtrak |
| Agios Pharmaceuticals, INC. | $65.83 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $65.35 | 2020-2021 | |
| Mirati Therapeutics, INC. | $64.02 | 2023 | Krazati |
| Emd Serono, INC. | $55.50 | 2024 | |
| Genentech, INC. | $53.45 | 2023 | Perjeta |
| Mylan Institutional INC. | $34.69 | 2023 | Ogivri, Fulphila |
| Genmab U.S., INC. | $33.15 | 2025 | Epkinly |
| Taiho Oncology, INC. | $30.95 | 2019 | |
| Blueprint Medicines Corporation | $27.72 | 2020 | |
| Beone Medicines USA, INC. | $26.11 | 2025 | Brukinsa |
| Sobi, INC | $25.87 | 2025 | |
| Gilead Sciences, INC. | $25.29 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $23.93 | 2019 | |
| Kite Pharma, INC. | $23.78 | 2024 | Yescarta |
| Jazz Pharmaceuticals INC. | $18.53 | 2020 | |
| Astellas Pharma US INC | $18.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.